Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

NCT07584954 is registered in ClinicalTrials.gov with Jun Zhou as lead sponsor.

NCT NCT07584954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07584954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
Lead sponsor
Jun Zhou
Phase
Phase 1
Overall status
Recruiting
Start date
June 18, 2024
Completion date
June 30, 2028
Enrollment
90 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor cancer, solid tumor cancer treatment with immunotherapy